|
American Cancer Society
ACS has exciting updates to share about changes to their postdoctoral fellowship program, their new AHEAD Awards, and more. Visit the Apply for a Grant page on cancer.org for full details about American Cancer Society research funding opportunities.
Additional Details
April 6, 2023
NCI Research Opportunity Announcement (ROA) : All of Us Center for Linkage and Acquisition of Data
This ROA is to solicit and review proposals, evaluate potential partners, and fund the future All of Us Center for Linkage and Acquisition of Data (CLAD). The intention of CLAD is to expand the type and research utility of program data by acquiring new passive data streams and providing additional methods to acquire data for existing data streams, such as electronic health records.
Additional Details
April 17, 2023
Leukemia & Lymphoma Society- Chronic Myelomonocytic Leukemia (CMML) Special Initiative
The purpose of the CMML Special Initiative is to establish a comprehensive research program to understand the unique characteristic of CMML, develop new targets and new therapies, and launch focused clinical programs needed to make significant progress toward cures for patients battling CMML. The grant program for the CMML Special Initiative will be comprised of two programs: a Synergistic Team Award (STA) similar to the LLS SCOR Program and a Translational Grant (TRL) similar to the LLS TRP Program.
Additional Details
May 1, 2023
NCCN and Pfizer Elranatamab and the treatment of Multiple Myeloma Research Opportunity
National Comprehensive Cancer Network® (NCCN®) is pleased to announce a collaboration with Pfizer Global Medical Grants (Pfizer) to offer a new grant opportunity. We are seeking Letters of Intent (LOIs) for investigator-initiated clinical research studies to further evaluate the effectiveness of elranatamab in the treatment of Multiple Myeloma. Please direct questions regarding this RFP to Nicole Zion at zion@nccn.org and Amanda Kaczerski at amanda.kaczerski@pfizer.com with the subject line, “NCCN Pfizer Myovant Elranatamab RFP.”
Additional Details
May 10,2023
NCCN, Pfizer, Myovant Prostate Cancer Clinical Research Opportunity
National Comprehensive Cancer Network® (NCCN®) is pleased to announce a collaboration with Pfizer Global Medical Grants (Pfizer) and Myovant Sciences (Myovant) to offer a new grant opportunity. We are seeking proposals for investigator-initiated research to support clinical research studies to further evaluate the effectiveness of relugolix in combination with other therapies for the treatment of advanced prostate cancer.
Additional Details
May 22, 2023
Liver Cancer Collaborative Projects with the Liver Cirrhosis Network
Through this funding opportunity, NCI intends to establish collaborations between liver cancer investigators and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-funded Liver Cirrhosis Network (LCN) members to advance our understanding of hepatocellular carcinoma as the result of liver cirrhosis and its etiologic risks, development, progression, early diagnosis, and treatment.
Additional Details
June 3, 2023
NIH/NCI Research Specialist (Clinician Scientist) Award
The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional clinician scientists who want to continue to participate in the NCI clinical trials networks through leadership in the 1) development of national clinical trials, 2) implementation of NCI clinical trials in their institutions, and 3) national service to the NCI clinical trials networks through participation in the scientific review committees, monitoring committees and other activities, but not serve as principal investigators of research project grants. These clinician scientists are vital to sustaining the NCI-funded clinical trials enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others or other sources of support for cancer research career continuity.
Additional Details
Rolling basis through October 6, 2023
Notice of Special Interest (NOSI): Technology Development for Cancer Control and Population Science Research
The purpose of this NOSI is to encourage grant applications for the development of novel technologies to support the needs of cancer control and population sciences research including healthcare delivery research, surveillance research, behavioral research, cancer epidemiology, and population scale -omics research with the goal of driving innovation in this field.
Additional Details
December 31, 2024
Impacts of Climate Change Across the Cancer Control Continuum R01 Clinical Trial Optional
These funding opportunities aim to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control, and behaviors.
Additional Details
May 8 2026
Impacts of Climate Change Across the Cancer Control Continuum R21 Clinical Trial Optional
These funding opportunities aim to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control, and behaviors.
Additional Details
May 8 2026
|
